Complications neurologiques centrales des traitements anticancéreux, ce que le réanimateur doit savoir

Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY, (2009) CNS complications of radiotherapy and chemotherapy. Lancet 374: 1639–1651 Créange A, Felten D, Kiesel I, Renard JL, Vespignani H, Béquet D, (1994) Subacute leukoencephalopathy of the rhombencephalon after pituitary radiotherapy. Rev Neurol (Paris) 150: 704–708 Lo Y, Shen LJ, Chen WH, Dong YH, Wu FL, (2016) Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: a retrospective analysis. J Formos Med Assoc Taiwan Yi Zhi 115: 744–751 Richards A, Marshall H, McQuary A, (2011) Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamiderelated neurotoxicity. J Oncol Pharm Pract 17: 372–380 Yeo KK, HaDuong JH, (2016) The use of continuous venovenous hemodiafiltration in the management of ifosfamideinduced encephalopathy: a case report. J Pediatr Hematol Oncol 38: 489–490 Carreras E, Cahn JY, Puozzo C, Kröger N, Sanz G, Buzyn A, Bacigalupo A, Vernant JP, (2010) Influence on Busilvex® pharmacokinetics of clonazepam compared to previous phenytoin historical data. Anticancer Res 30: 2977–2984 Stein AS, O’Donnell MR, Chai A, Schmidt GM, Nademanee A, Parker PM, Smith EP, Snyder DS, Molina A, Stepan DE, Spielberger R, Somlo G, Margolin KA, Vora N, Lipsett J, Lee J, Niland J, Forman SJ, (1996) In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. J Clin Oncol 14: 2206–2216 Bleyer A, (2007) “Flushing out” cytosine arabinoside from CSF to reverse neurotoxicity. J Pediatr Hematol Oncol 29: 274 Gállego Pérez-Larraya J, Palma JA, Carmona-Iragui M, Fernández-Torrón R, Irimia P, Rodríguez-Otero P, Panizo C, Martínez-Vila E, (2011) Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma. J Neurooncol 103: 603–609 Fyfe G, Fisher RI, Rosenberg SA Sz nol M, Parkinson DR, Louie AC, (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688–696 Atkins MB, Lotze MT, Dutcher JP Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA, (1999) High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105–2116 Lerner DM, Stoudemire A, Rosenstein DL, (1999) Neuropsychiatric toxicity associated with cytokine therapies. Psychosomatics 40: 428–435 Merimsky O, Chaitchik S, (1992) Neurotoxicity of interferonalpha. Anticancer Drugs 3: 567–570 Quarantini LC, Miranda-Scippa A, Parana R, Sampaio AS, Bressan RA, (2007) Acute dystonia after injection of pegylated interferon alpha-2b. Mov Disord 22: 747–748 Yi HJ, Hong KS, Moon N, Chung SS, Lee RA, Kim KH, (2016) Acute hyperammonemic encephalopathy after 5-fluorouracil based chemotherapy. Ann Surg Treat Res 90: 179–182 Koenig H, Patel A, (1970) Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 23: 155–160 Shimoyama R, Ban T, Miyake K, Isogai N, Ikegaya Y, Kawachi J, Ogino H, Watanabe K, (2014) Early diagnosis of capecitabineinduced acute leukoencephalopathy by using diffusion-weighted MRI. Gan To Kagaku Ryoho 41: 1251–1253 Taguchi Y, Takashima S, Tanaka K, (2015) A case of phenytoin intoxication caused by interaction between phenytoin and capecitabine. Brain Nerve Shinkei Kenkyu No Shinpo 67: 213–217 Pirzada NA, Ali II, Dafer RM, (2000) Fluorouracil-induced neurotoxicity. Ann Pharmacother 34: 35–38 Beitinjaneh A, McKinney AM, Cao Q, Weisdorf DJ, (2011) Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant 17: 300–308 Merkel DE, Griffin NL, Kagan-Hallet K, Von Hoff DD, (1986) Central nervous system toxicity with fludarabine. Cancer Treat Rep 70: 1449–1450 Chun HG, Leyland-Jones BR, Caryk SM, Hoth DF, (1986) Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 70: 1225–1228 Newton HB, (2012) Neurological complications of chemotherapy to the central nervous system. Handb Clin Neurol 105: 903–916 Thust SC, Blanco E, Michalski AJ, Chong WK, Gaze MN, Phipps K, Mankad K, (2014) MRI abnormalities in children following sequential chemotherapy, hyperfractionated accelerated radiotherapy and high-dose thiotepa for high-risk primitive neuroectodermal tumours of the central nervous system. J Med Imaging Radiat Oncol 58: 683–690 Szabatura AH, Cirrone F, Harris C, McDonnell AM, Feng Y, Voit D, Neuberg D, Butrynski J, Fisher DC, (2015) An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. J Oncol Pharm Pract 21: 188–193 Buie LW, Epstein SS, Lindley CM, (2007) Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther 29: 1887–1899 Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB; Children’s Oncology Group, (2005) Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J Clin Oncol 23: 3376–3382 Sathiapalan RK, El-Solh H, (2001) Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature. Pediatr Hematol Oncol 18: 543–546 Chotsampancharoen T, Sripornsawan P, Wongchanchailert M, (2016) Two fatal cases of accidental intrathecal vincristine administration: learning from death events. Chemotherapy 61: 108–110 Goss P, Stewart AK, Couture F, Klasa R, Glück S, Kaizer L, Burkes R, Charpentier D, Palmer M, Tye L, Dulude H, (1999) Combined results of two phase II studies of Taxol™ (paclitaxel) in patients with relapsed or refractory lymphomas. Leuk Lymphoma 34: 295–304 Moore-Maxwell CA, Datto MB, Hulette CM, (2004) Chemotherapy-induced toxic leukoencephalopathy causes a wide range of symptoms: a series of four autopsies. Mod Pathol 17: 241–247 Markman M, (2003) Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf 2: 597–607 Holman LL, Ren Y, Westin SN, (2015) Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case report. BMC Cancer 15: 728 Sohlbach K, Heinze S, Shiratori K, Sure U, Pagenstecher A, Neubauer A, (2006) Encephalopathy in a patient after long-term treatment with thalidomide. J Clin Oncol 24: 4942–4944 Singer S, Grommes C, Reiner AS, Rosenblum MK, DeAngelis LM, (2015) Posterior reversible encephalopathy syndrome in patients with cancer. Oncologist 20: 806–811 Helissey C, Chargari C, Lahutte M, Ricard D, Vedrine L, Ceccaldi B, Le Moulec S, (2012) First case of posterior reversible encephalopathy syndrome associated with vinflunine. Invest New Drugs 30: 2032–2034 Psimaras D, Bompaire F, Taillia H, Ricard D, Taillibert S, (2012) Central nervous system complications in patients undergoing cytotoxic chemotherapy and targeted therapies. Bull Cancer (Paris) 99: 851–863 Kamiya-Matsuoka C, Paker AM, Chi L, Youssef A, Tummala S, Loghin ME, (2016) Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neurooncol 128: 75–84 Sharief U, Perry DJ, (2009) Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin. Clin Colorectal Cancer 8: 163–165 Verschraegen C, Conrad CA, Hong WK, (1995) Subacute encephalopathic toxicity of cisplatin. Lung Cancer Amst Neth 13: 305–309 Berman IJ, Mann MP, (1980) Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer 45: 764–766 Song T, Rao Z, Tan Q, Qiu Y, Liu J, Huang Z, Wang X, Lin T, (2016) Calcineurin inhibitors associated posterior reversible encephalopathy syndrome in solid organ transplantation: report of 2 cases and literature review. Medicine (Baltimore) 95: e3173 Truong QV, Abraham J, Nagaiah G, Newton M, Veltri L, (2012) Gemcitabine associated with posterior reversible encephalopathy syndrome (PRES): a case report and review of the literature. Clin Adv Hematol Oncol HO 10: 611–613 Teh HS, Fadilah SA, Leong CF, (2007) Transverse myelopathy following intrathecal administration of chemotherapy. Singapore Med J 48: e46–e49 LaPorte J, Solh M, Ouanounou S, (2015) Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma. Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma. J Oncol Pharm Pract [in press] Khoja L, Maurice C, Chappell M, MacMillan L, Al-Habeeb AS, Al-Faraidy N, Butler MO, Rogalla P, Mason W, Joshua AM, Hogg D, (2016) Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res 4: 175–178 Badke C, Fleming A, Iqbal A, Khilji O, Parhas S, Weinstein J, Morgan E, Hijiya N, (2016) Rechallenging with intrathecal methotrexate after developing subacute neurotoxicity in children with hematologic malignancies. Pediatr Blood Cancer 63: 723–726 Tzachanis D, Haider M, Papazisis G, (2016) A case of subacute encephalopathy developing after treatment with clofarabine and methotrexate that resolved with corticosteroids. Am J Ther 23: e937–e940 Correa DD, Shi W, Thaler HT, Cheung AM, DeAngelis LM, Abrey LE, (2008) Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol 86: 321–327 Lee HC, Mulanovich V, Nieto Y, (2014) Progressive multifocal leukoencephalopathy after allogeneic bone marrow transplantation for acute myeloid leukemia. J Natl Compr Cancer Netw JNCCN 12: 1660–1664; quiz 1664 Antonsson A, Pawlita M, Feltkamp MCW, Bouwes Bavinck JN, Euvrard S, Harwood CA, Naldi L, Nindl I, Proby CM, Neale RE, Waterboer T, (2013) Longitudinal study of seroprevalence and serostability of the human polyomaviruses JCV and BKV in organ transplant recipients. J Med Virol 85: 327–335 Waggoner J, Martinu T, Palmer SM, (2009) Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant 28: 395–398 Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL, (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports Project. Blood 113: 4834–4840 Silverio KA, Patel SA, (2015) Progressive multifocal leukoencephalopathy with negative JC virus PCR following treatment of follicular lymphoma: implications for biologics in the era of targeted cancer therapy. Case Rep Oncol Med 2015: 534529 Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, Moskowitz AJ, Rook AH, Jalan P, Loren AW, Landsburg D, Coyne T, Tsai D, Raisch DW, Norris LB, Bookstaver PB, Sartor O, Bennett CL, (2014) Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) Project. Cancer 120: 2464–2471 El Amrani M, Aidi S, Amarenco P, (2003) Cerebral ischemic events and anti-cancer therapy. Rev Neurol (Paris) 159: 371–380 Mitchell L, Lambers M, Flege S, Kenet G, Li-Thiao-Te V, Holzhauer S, Bidlingmaier C, Frühwald MC, Heller C, Schmidt W, Pautard B, Nowak-Göttl U, (2010) Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood 115: 4999–5004 Izzedine H, Perazella MA, (2015) Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 66: 857–868 Richmond J, Gilbar P, Abro E, (2013) Gemcitabine-induced thrombotic microangiopathy. Intern Med J 43: 1240–1242